Para poder acceder a la web de la GT debes tener el código de registro de la 8a edición de la Guía. No son válidos los códigos de ediciones anteriores. Si no has registrado tu código, debes hacerlo aquí.

Registrarse

¿Has olvidado la contraseña?

Para cualquier consulta o incidencia, puedes contactarnos a través del correo guiaterapeutica@semfyc.es

Enfermedades infecciosas no incluidas en las otras unidades

  • BMJ Publishing Group. Evidencia clínica. 2 ed. Bogotá: Legis; 2003.
  • CDC. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR 2007;56:332-6.
  • Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59(N.RR-12):1-95.
  • Grupo de expertos de GESIDA y del Plan Nacional sobre el Sida. Documento de consenso sobre las infecciones de transmisión sexual en personas con infección por el VIH (Septiembre 2010). Disponible en: http://www.msps.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/docConsensoITSSept10.pdf
  • Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis 2006;42:1075-80.
  • Hellín T, Rodríguez A, Ribera E. Enfermedades de transmisión sexual. Protocolos clínicos de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica [en línea]. [Consulta realizada el 22 Feb 2004]. Disponible en: http://www.seimc.org/protocolos/clinicos/index.htm.
  • Mensa J, Gatell J, García-Sánchez J, Letang E, López-Suñe E. Guía de Terapéutica Antimicrobiana 2010. 20 ed. Barcelona: Masson; 2010.
  • National Guidelines on the Management of Suspected Sexually Transmitted Infections in Children and Young People 2010. BASHH Clinical Effectiveness Group. Disponible en: http://www.bashh.org/guidelines
  • SemFYC. Infecciones agudas en el adulto. FMC 1998;5(Supl 9):1-242.

Brucelosis

  • Everett ED. Brucellosis in children. UpToDate, 2007. Disponible en: http://patients.uptodate.com/topic.asp?file=pedi_id/7228&title=Brucellosis.
  • Keramat F, Ranjbar M, Mamani M, Hashemi SH, Zeraati F. A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. Trop Doct. 2009 Oct;39(4):207-10.
  • Roushan MR, Amiri MJ, Janmohammadi N, Hadad MS, Javanian M, Baiani M, et al. Comparison of the efficacy of gentamicin for 5 days plus doxycycline for 8 weeks versus streptomycin for 2 weeks plus doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial. J Antimicrob Chemother. 2010 May;65(5):1028-35. Epub 2010 Mar 9.
  • Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005;352:2325-36.
  • Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007;4(12):e317.
  • Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008;336:678-9.
  • Solera J. Update on brucellosis: therapeutic challenges. Int J Antimicrob Agents. 2010;36(Suppl 1): S18-20.

Chancroide

  • Hicks Ch. Chancroid. En: UpToDate, Issue 1, 2008.
  • Holland-Hall C. Sexually transmitted infections: screening, syndromes, and symptoms. Prim Care. 2006;33:433-54.
  • Kaliaperumal K. Recent advances in management of genital ulcer disease and anogenital warts. Dermatol Ther 2008;21:196-204.
  • Lewis DA, Ison CA. Chancroid. Sex Transm Infect 2006;82(Suppl 4):iv19-20.
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. 2010;59:RR12.
  • Enfermedades de transmisión sexual (en agresiones sexuales)
  • Clinical Effectiveness Group. Group 2002 National Guidelines on the Management of Adult Victims of Sexual Assault. Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases [en línea]. [Consulta realizada el 22 Feb 2004]. Disponible en: http://www.guideline.gov/summary/summary.aspx?doc_id=3050.
  • Cybulska B, Forster G, Welch J, Lacey H, Rogstad K, Lazaro N. Clinical Effectiveness Group British Association for Sexual Health and HIV. UK National Guidelines on The Management of Adult and Adolescent Complainants of Sexual Assault 2011. London (UK): British Association for Sexual Health and HIV; 2011.
  • Fisher M, Benn P, Evans B. Clinical Effectiveness Group (British Association for Sexual Health and HlV). UK Guideline for the use of post- exposure prophylaxis for HIV following sexual exposure. Int J STD & AIDS. 2006;17:81-92.
  • Forrest L. Patient initiated aggression and violence in Australian general practice. Aust Fam Physician. 2010;39:323-6.
  • Hack JB, Hecht C. Emergency physicians' patterns of treatment for presumed gonorrhea and chlamydia in women: one center's practice. J Emerg Med 2008;31.
  • Heke S, Forster G, D'Ardenne P. Risk identification and management of adults following acute sexual assault. Sexual and Relationship Therapy. 2009;24:4-15.
  • Kaufman M and the Committee on Adolescence. Care of the Adolescent Sexual Assault Victim. Pediatrics. 2008;122:462-70.
  • Recomendaciones de la SPNS/GESIDA/AEP/ CEEISCAT/SEMP sobre la profilaxis postexposición frente al VIH, VHB y VHC en adultos y niños (Enero 2008). Disponible en: http://www.gesida.seimc.org/pcientifica/fuentes/DcyRc/Gesida_dcyrc200801_profilaxispostexposicion.pdf
  • Sapp MV, Vandeven AM. Update on childhood sexual abuse. Curr Opin Pediatr 2005;17:258-6.
  • Welch J, Mason F. Rape and sexual assault. BMJ 2007 Jun 2;334(7604):1154-8.
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59:RR12.

Fiebre botonosa mediterránea

  • Botelho-Nevers E, Rovery C, Richet H, Raoult D. Analysis of risk factors for malignant Mediterranean spotted fever indicates that fluoroquinolone treatment has a deleterious effect. J Antimicrob Chemother. 2011;66(8):1821-30.
  • Garnier JM, Jurquet AL, Retornaz K, Fournier PE, Minodier P. Pediatric Mediterranean spotted fever. Arch Pediatr. 2009;16(Suppl 2):S93-5.
  • Kallinich T, Haffner D, Niehues T, Huss D, Lainka E, Neudorf U, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007;119:e474.
  • Mert A, Ozaras R, Tabak F, Bilir M, Ozturk R. Mediterranean spotted fever: a review of fifteen cases. J Dermatol 2006;33:103-7.
  • Rosenberg PM, Goldfinger SE. Management of familial Mediterranean fever. UpToDate 2008.

Granuloma inguinal

  • CDC. Workowski KA, Berman SM. Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR 2006;55 (RR11);1-94.
  • Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59(No. RR-12):1-95.
  • Queensland sexual health, Clinical management guidelines 2010. Disponible en: http://www.health.qld.gov.au/sexhealth/documents/cm_guidelines.pdf
  • Richens J. Donovanosis (granuloma inguinale). Sex Transm Infect 2006 Dec;82(Suppl 4):iv21-2. No abstract available.
  • Rosen T, Vandergriff T, Harting M. Antibiotic Use in Sexually Transmissible Diseases. Dermatologic Clinics. 2009;27:1.
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. 2010;59:RR12.

Hepatitis crónica por VHC

  • Agarwal K, Cross TJ, Gore C. Chronic hepatitis C. BMJ 2007;334:54-5.
  • Association E. EASL clinical practical guidelines: Management of alcoholic liver disease. J Hepatol. 2012;57(2):399-420.

  • Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51(4):1176-84.
  • Chopra S, Bisceglie. Treatment of chronic hepatitis C virus infection: Recommendations for adults. UpToDate, 2008.
  • Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006;130:225.
  • Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Hermann E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clinical Gastroenterol Hepatol. 2010;8:884-90.
  • Grupo de Trabajo de Enfermedades Infecciosas de la semFYC. Manual de enfermedades infecciosas en Atención Primaria 4.a edición. Barcelona: Congreso y Ediciones SemFYC; 2017.
    Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2.444-51.
  • Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD004888.
  • Jacobson IM, McHutchinson JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16.
  • Mohsen A, Norris S. Hepatitis C Crónica. Evid Clin Concisa 2006;5:206-8.
  • Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. NICE technology appraisal guidance 200 (2010). Disponible en: http://www.nice.org.uk/nicemedia/live/13180/50856/50856.pdf
  • Pitarch Nácher C, Benítez Camps M. Abordaje de la hipertransaminasemia en Atención Primaria. AMF. 2015; 11 (7): 392-9.
  • Poordad F, McCone J, Bacon BR, et al; SPRINT-2 Investigators. Bocepravir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206.
  • Wilkins T, Malcolm JK, Raina D, Schade RR. Hepatitis C: diagnosis and treatment. Am Fam Physician. 2010;81:1351-7.
  • Wilkins T, Tadkod A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician. 2013;88: 35-42.

Hepatitis vírica aguda

  • Corey KE, Ross AS, Wurcel A, Schulze zur Wiesch J, Kim AY, Lauer GM, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 2006;4:1278-1282.
  • Corey KE, Servoss JC, Casson DR, Kim AY, Robbins GK, Franzini J et al. Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol. 2009;30(10):1000.

  • Curry MP, Chopra S. Acute Viral Hepatitis. En: Mandell: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 7th ed. Philadelphia: Churchill Livongstone Elsevier; 2010.
  • Gluud LL. Meta-analyses on viral hepatitis. Infect Dis Clin North Am. 2009;23:315-30.
  • Lorenz R, Endres S. Diagnosis and treatment of acute hepatitis C in adults. UpToDate 2008.
  • Petruff C. Overview of hepatitis A virus infection in adults. UpToDate 2008.
  • Shiffman ML. Management of acute hepatitis B. Clin Liver Dis. 2010 Feb;14(1):75-91; viii-ix.
  • Wilkins T, Zimmerman D, Schade RR. Hepatitis B: diagnosis and treatment. Am Fam Physician. 2010;81:965-72.
  • Wong SN, Lok ASF. Treatment of hepatitis B. Who, when, and how? Arch Intern Med 2006;166:9-12.

Linfogranuloma venéreo

  • 2006 national guideline for the management of lymphogranuloma venereum. British Association for Sexual Health and HIV - Medical Specialty Society. 1999 Aug (revised 2006 May).
  • Collins L, White JA. Lymphogranuloma venereum. BMJ 2006;332:66.
  • Gilleece Y, Sullivan A. Management of sexually transmitted infections in HIV positive individuals. Curr Opin Infect Dis 2005;18:43-7.
  • Jebbari H, Alexander S, Ward H, Evans B, Solomou M, Thornton A, et al. UK LGV Incident Group. Update on lymphogranuloma venereum in the United Kingdom. Sex Transm Infect 2007;83:324-6.
  • Scottish Intercollegiate Guidelines Network. Management of genital Chlamydia trachomatis infection. A national clinical guideline. Disponible en: http://www.sign.ac.uk/pdf/sign109.pdf
  • US Centers for Disease Control and Prevention. Drugs for sexually transmitted infections. Treat Guidel Med Lett. 2007;5:81-8.
  • White JA. Manifestations and management of lymphogranuloma venereum. Clin Microbiol Infect. 2009;15:4-10.
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. 2010;59:RR12.
  • Profilaxis del defecto del tubo neural
  • Mahmud M, Mazza D. Preconception care of women with diabetes: a review of current guideline recommendations. BMC Womens Health. 2010;10:5.
  • Profilaxis primaria y secundaria de VIH/sida para neumonía por P. jiroveci (carinii) y toxoplasmosis
  • Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:651-81.
  • Brooks JT, Kaplan JE, Masur H. What's new in the 2009 US guidelines for prevention and treatment of opportunistic infections among adults and adolescents with HIV? Top HIV Med. 2009;17:109-14.
  • Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-exposed and infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2004;53(RR-15):1-112. Erratum in: MMWR Morb Mortal Wkly Rep. 2005;54:311.
  • Grupo de trabajo VIH/sida de la semFYC. Infección por el VIH: preguntas y respuestas desde Atención Primaria. Barcelona: semfyc ediciones; 2006
  • Ioannidis J, Wilkinson D. Prevención de las infecciones oportunistas en pacientes con infección por VIH. Evid Clín Concisa 2006;5:653-7.
  • Krajicek BJ, Thomas CF, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med. 2009;30:265-78.
  • Madge S, Matthews P, Singh S, Theobald N. HIV in Primary Care. Disponible en: http://www.medfash.org.uk/publications/documents/HIV_in_Primary_Care.pdf
  • Mofenson LM, Brady MT, Danner SP, Domínguez KL, Hazra R, Handelsman E, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58(RR-11):1-166.
  • Recomendaciones de Gesida/Plan Nacional sobre el sida. Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH en la era del tratamiento antirretroviral de gran actividad [en línea]. [Consulta realizada el 12 Feb 2004]. Disponible en: http://www.msc.es/profesional/preProSalud/sida/pdfs/rec16.pdf
  • Teshale, EH, Hanson, DL, Wolfe, MI, Brooks JT, Kaplan JE, Bort Z, et al. Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003. Clin Infect Dis 2007;44:879.
  • Tiejten PA, Bartlett JG. Prophylaxis against Pneumocystis carinii (P. jiroveci) in HIV-infected patients. Disponible en: http://www.uptodate.com

Quimioprofilaxis de la enfermedad meningocócica

  • Apicella M. Treatment and prevention of meningoccal infection. Disponible en: http://www.uptodate.com
  • Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54(RR-7):1-21.
  • Correia JB, Hart CA. Enfermedad meningocócica. Evid Clin Concisa 2006;5:194-7.
  • Fekete T, Quagliarello V. Treatment and prevention of bacterial meningitis in adults. UpToDate 2008.
  • Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database of Systematic Reviews. 2006, Issue 4.
  • Kimmel SR. Prevention of meningococcal disease. Am Fam Physician. 2005;72:2049-56.
  • van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med 2006;354:44.

Sífilis

  • Bai ZG, Wang B, Yang K, Tian JH, Ma B, Liu Y, et al. Azithromycin versus penicillin G benzathine for early syphilis. Cochrane Database of Systematic Reviews 2012, Issue 6.
  • Brown DL, Frank JE. Diagnosis and management of syphilis. Am Fam Physician 2003;68:283-90.
  • French P, Gomberg M, Janier M, et al. IUSTI: 2008 European guideline on the management of syphilis. Int J STD AIDS. 2009;20:300-9.
  • Hicks ChB, Sparling PF. Pathogenesis, clinical manifestations, and treatment of late syphilis. UpToDate 2008.
  • Holmes KK. Azithromycin versus penicillin G benzathine for early syphilis. N Engl J Med 2005;353:1291-3.
  • Kingston M, French P, Gih B, Goold P, Higgins S, Sukthankar A, et al. UK National Guidelines on the Management of Syphilis 2008. International Journal of STD & AIDS. 2008;19:729-40.
  • Majeroni BA, Ukkadam S. Screening and treatment for sexually transmitted infections in pregnancy. Am Fam Physician. 2007;76:265-70.
  • New York State Department of Health. Syphilis. New York (NY): New York State Department of Health; 2009. Disponible en: http://www.guideline.gov/content.aspx?id=15092
  • Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR Recomm Rep 2006;55(R11):1-94.
  • Walker GJA. Antibiotics for syphilis diagnosed during pregnancy. Cochrane Database of Systematic Reviews. 2001, Issue 3. Art. No.: CD001143. DOI: 10.1002/14651858.CD001143
  • Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR. 2010;59:RR12.

Toxoplasmosis en el embarazo (infección reciente)

  • Goldenberg RL, Culhane JF, Johnson DC. Maternal infection and adverse fetal and neonatal outcomes. Clin Perinatol. 2005;32:523-59.
  • Goldstein RC, Luft BJ. Toxoplasmosis. En: Bope ET, Kellerman R, Rakel R, eds. Bope: Conn's Current Therapy 2011, 1st ed. Philadelphia: Elsevier Saunders; 2010.
  • Jones J, López A, Wilson M. Congenital Toxoplasmosis. Am Fam Physician. 2003;67:2131-8.
  • Muñoz C, Guardià C, Juncosa T, Viñas Ll, Sierra M, Sanfeliu I, et al. Toxoplasmosis y embarazo. Estudio multicéntrico realizado en 16.362 gestantes de Barcelona. Med Clin (Barc) 2004;123:12-6.

Tuberculosis

  • American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care. 2005;172:1169-227.
  • Domínguez-Castellano A, Del Arco A, Canueto-Quintero J, Rivero-Román A, Kindelán JM, Creagh R, et al. Guía de práctica clínica de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI) sobre el tratamiento de la tuberculosis. Enferm Infecc Microbiol Clin. 2007;25:519-34.
  • Garcés F, Tótola D, Rodríguez R, Cereceda M, Salvo E. Tuberculosis pulmonar. En: Arranz J, Cots JM, Gómez M, Monedero MJ, eds, Grupo de enfermedades infecciosas. Manual de enfermedades infecciosas en Atención Primaria. 2ª ed. Sociedades Balear, Catalana, Madrileña y Valenciana de Medicina Familiar y Comunitaria. Madrid: semFYC-ediciones; 2005. p.47-71.
  • García S, Roca D. Tuberculosis. A propósito de un caso. AMF 2013;9(8):447-456.
  • Gómez M, Rodríguez R. Atención al enfermo con tuberculosis. En: Guía de actuación en Atención Primaria. 4ºed. Madrid: semFYC-ediciones; 2011. p.1687-93.
  • Gómez M, Redondo JM. Estudio de contactos de enfermos de tuberculosis. AMF 2017;13(11):648-652.
  • González-Marín J, García-García JM, Anibarro L, Vidal R, Esteban J, Blanquer R et al. Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis. Arch Bronconeumol. 2010; 46(5): 213-284.
  • Grupo de Estudios de Contactos de la Unidad de Investigación en Tuberculosis de Barcelona (UITB). Documento de consenso sobre estudios de contactos en los pacientes tuberculosos. Med Clin (Barc). 1999;112:151-6.
  • National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians; 2006.

Uretritis